Home > Insider Trading > Filing (0000914190-16-000517)

Filing Details

Accession Number:: 0000914190-16-000517
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-01-14 17:19:48
Reporting Period:: 2016-01-12

Filing Date:: 2016-01-14
Accepted Time:: 2016-01-14 17:19:48
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1195116	Arno Therapeutics Inc	ARNI	Pharmaceutical Preparations (2834)	522286452

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1296549	Arie Belldegrun	C/O Arno Therapeutics, Inc. 200 Route 31 North, Suite 104 Flemington NJ 08822		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-01-12	1,448,062	$0.35	1,548,543	No	4	P	Indirect	Arie S. Belldegrun, M.D. Inc. Profit Sharing Plan
Common Stock	Acquisiton	2016-01-12	714,285	$0.35	858,094	No	4	P	Indirect	Leumi Overseas Trust Corp. Ltd. as TTEE of the BTL Trust

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Arie S. Belldegrun, M.D. Inc. Profit Sharing Plan
No	4	P	Indirect	Leumi Overseas Trust Corp. Ltd. as TTEE of the BTL Trust

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	3,115	Direct
Common Stock	254,887	Indirect	Leumi Overseas Trust Corp. Ltd. as TTEE of the Tampere Trust
Common Stock	379,294	Indirect	Belldegrun Family Trust
Common Stock	174,644	Indirect	MDRB Partnership, L.P.

Reported Derivative Holdings

Show Other Fields >>

Sec. Name	Sec. Type	Price	Date	Expiration Date	Amount	Remaning Holdings	Nature of Ownership
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-11-26	2017-11-26	245,096	245,096	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	194,702	194,702	Indirect
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-11-26	2017-11-26	367,646	367,646	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	194,702	194,702	Indirect
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-11-26	2017-11-26	428,920	428,920	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	350,467	350,467	Indirect
Common Stock	2012 Series A Warrants (right to buy)	$1.36	2012-11-26	2017-11-26	183,822	183,822	Indirect
Common Stock	2013 Series D Warrants (right to buy)	$2.14	2013-10-29	2018-10-29	155,762	155,762	Indirect
Common Stock	Stock Option (right to buy)	$19.36		2018-03-31	24,922	24,922	Direct
Common Stock	Stock Option (right to buy)	$8.00		2019-09-29	1,250	1,250	Direct
Common Stock	Stock Option (right to buy)	$8.00		2020-09-09	37,500	37,500	Direct
Common Stock	Stock Option (right to buy)	$8.00		2020-11-05	1,250	1,250	Direct
Common Stock	Stock Option (right to buy)	$2.40		2023-11-04	3,559,296	3,559,296	Direct
Common Stock	Stock Option (right to buy)	$2.90		2024-01-24	68,448	68,448	Direct

Expiration Date	Amount	Remaning Holdings	Nature of Ownership
2017-11-26	245,096	245,096	Indirect
2018-10-29	194,702	194,702	Indirect
2017-11-26	367,646	367,646	Indirect
2018-10-29	194,702	194,702	Indirect
2017-11-26	428,920	428,920	Indirect
2018-10-29	350,467	350,467	Indirect
2017-11-26	183,822	183,822	Indirect
2018-10-29	155,762	155,762	Indirect
2018-03-31	24,922	24,922	Direct
2019-09-29	1,250	1,250	Direct
2020-09-09	37,500	37,500	Direct
2020-11-05	1,250	1,250	Direct
2023-11-04	3,559,296	3,559,296	Direct
2024-01-24	68,448	68,448	Direct

Footnotes

On January 12, 2016, the Arie Belldegrun M.D., Inc. Profit Sharing Plan was issued 1,448,062 shares upon the automatic conversion of $506.821.92 of principal and accrued interest under a 6% unsecured convertible promissory note previously issued to the Arie Belldegrun M.D., Inc. Profit Sharing Plan by the Issuer on October 21, 2015.
The Reporting Person is the trustee of the profit sharing plan that owns the securities.
Although the Reporting Person is not a trustee of the BTL Trust, the Reporting Person is a beneficiary of the BTL Trust, and as such may be deemed to be the beneficial owner of the securities owned by the BTL Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Although the Reporting Person is not a trustee of the Tampere Trust, the Reporting Person is a beneficiary of the Tampere Trust, and as such may be deemed to be the beneficial owner of the securities owned by the Tampere Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The Reporting Person is the trustee of the family trust that owns the securities. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
The Reporting Person is the managing partner of the limited partnership that owns the securities. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
As a result of the Issuer's 1/12/16 private placement of common stock at $0.35/share, the exercise price and number of shares subject to the 2012 Series A Warrants and 2013 Series D Warrants were automatically adjusted to the exercise price and shares reflected, pursuant to anti-dilution adjustment provisions.
Currently exercisable.
Vests in equal 36-monthly installments commencing 12/4/13.
Vests in equal 12-monthly installments commencing 2/24/14.